Published on : Aug 01, 2017
Albany, New York, August 1, 2017: Ulceration within the duodenum is a common surgical complaint with a wide spectrum of type and severity of presentation. Research has examined that treatment for duodenal ulcers has changed significantly over the last couple of decades. Earlier, most patients with duodenal ulcers had to have their abdomens cut open and surgery performed, today patients are treated by a combination of drugs that reduce the exposure of the stomach lining to acid. A recent pipeline study, titled “Duodenal Ulcer - Pipeline Insight, 2017” has been published to the wide research portfolio of Market Research Hub (MRH), which provides information on the therapeutic development for Duodenal Ulcer, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products.
A person gets a duodenal ulcer when the duodenum in the stomach is affected by the H. pylori bacteria. Duodenal ulcer occurs to both sexes and regardless of age. However, statistics indicate that male persons are more likely to develop forms of duodenal ulcer than women. In order to prevent the development of either gastric or duodenal ulcer, it is important to control alcohol and caffeine intake. The primary symptoms of a duodenal ulcer are heartburn, severe stomach pain, unplanned weight gain, and a burning sensation felt at the back of the throat.
This latest study offering pipeline therapeutics covers detailed overview of pipeline products for duodenal ulcer. This section of the report is followed by therapeutic assessment of all the active products by route of administration, clinical stage and molecule type. Through this pipeline analysis, the report aims to establish the understanding for all the pipeline drugs that are undergoing research across Duodenal Ulcer. In the past, surgery was commonly needed to treat a duodenal ulcer. At present, it has been analyzed that the vast majority of duodenal ulcers will heal with a six-week course of acid suppression therapy using a proton pump inhibiting drug including Omeprazole, Esmoprazole etc. and eradication of Helicobacter Pylori (if present) with a week long course of two antibiotics in combination.
The discovery of a drug (cimetidine) that inhibits the flow of digestive acids and enzymes and thereby permits ulcers to heal has markedly changed ulcer therapy. An estimated 25 million people worldwide have received cimetidine therapeutically. The advances of cimetidine have been continued with the introduction of a second H2-receptor antagonist, ranitidine.
Moreover, the report contains details on dormant products and discontinued products of the active players involved in therapeutic market of duodenal ulcers. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the team of industry experts.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1214090
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com